Physician profile
Larry Allen
NPI 1669714663
$5,241.85
in general payments reported to CMS, 2019-2025
37 companies · $875 in 2025
The $875 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,225 · 2022: $993 · 2023: $1,290 · 2024: $859 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.38 | 2021-2025 | |
| Lilly USA, LLC | $570.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $473.00 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $384.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $249.33 | 2024-2025 | Voquezna |
| Pfizer INC. | $229.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $205.92 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $180.09 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.31 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $142.26 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $141.57 | 2021-2023 | Belsomra, Steglatro, Steglujan |
| Amarin Pharma, INC. | $133.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $131.29 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $122.85 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $111.18 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $89.25 | 2021-2023 | |
| Amgen INC. | $66.59 | 2021-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $63.27 | 2021-2023 | Livalo, Seglentis |
| Dexcom, INC. | $61.38 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $59.77 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $58.71 | 2021-2024 | Loreev Xr, Gralise |
| Idorsia Pharmaceuticals US INC | $58.18 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $57.27 | 2021-2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $42.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.23 | 2022-2023 | Eliquis, Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $41.85 | 2022 | |
| Corcept Therapeutics | $40.77 | 2025 | Korlym |
| Mylan Specialty L.P. | $29.30 | 2021 | |
| Inspire Medical Systems, INC. | $28.76 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $24.47 | 2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.16 | 2023 | |
| Medtronic, INC. | $16.46 | 2021 | |
| Pulmonx Corporation | $16.38 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Shield Therapeutics INC | $14.82 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $12.82 | 2021 | |
| Eisai INC. | $12.02 | 2022 | |
| Genentech USA, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.